Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Arcus Biosciences (RCUS) Cash & Current Investments (2017 - 2025)

Arcus Biosciences (RCUS) has 9 years of Cash & Current Investments data on record, last reported at $981.0 million in Q4 2025.

  • For Q4 2025, Cash & Current Investments changed N/A year-over-year to $981.0 million; the TTM value through Dec 2025 reached $981.0 million, changed N/A, while the annual FY2025 figure was $981.0 million, N/A changed from the prior year.
  • Cash & Current Investments reached $981.0 million in Q4 2025 per RCUS's latest filing, up from $831.0 million in the prior quarter.
  • Across five years, Cash & Current Investments topped out at $1.2 billion in Q1 2022 and bottomed at $156.0 million in Q2 2024.
  • Average Cash & Current Investments over 5 years is $856.8 million, with a median of $920.5 million recorded in 2023.
  • Peak YoY movement for Cash & Current Investments: crashed 83.23% in 2024, then soared 483.97% in 2025.
  • A 5-year view of Cash & Current Investments shows it stood at $499.0 million in 2021, then skyrocketed by 102.2% to $1.0 billion in 2022, then decreased by 24.78% to $759.0 million in 2023, then skyrocketed by 43.48% to $1.1 billion in 2024, then dropped by 9.92% to $981.0 million in 2025.
  • Per Business Quant database, its latest 3 readings for Cash & Current Investments were $981.0 million in Q4 2025, $831.0 million in Q3 2025, and $911.0 million in Q2 2025.